Biodexa Pharmaceuticals (BDRX) Net Cash Flow (2013 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Net Cash Flow of -$111428.2 for Q4 2022, up 5.16% sequentially from -$117489.0 in Q3 2022, and up 63.75% YoY from -$68049.8 in Q4 2021.
Biodexa Pharmaceuticals (BDRX) Net Cash Flow (2013 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Net Cash Flow for 10 years, with the latest figure at -$111428.2 in Q4 2022.
- Quarterly Net Cash Flow rose 63.75% year-over-year to -$111428.2 in Q4 2022, while the trailing twelve-month figure through Dec 2025 was -$0.0 (changed 0.0% YoY) and the FY2025 annual result came in at $9.1 million, up 263.93% from the prior year.
- Net Cash Flow rose to -$111428.2 in Q4 2022 per BDRX's latest filing, from -$117489.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $8.6 million in Q4 2019 and troughed at -$9.0 million in Q4 2020.
- A 5-year average of -$1.8 million and a median of -$212417.7 in 2021 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2019 and 2020: Net Cash Flow soared 95722.48% in 2019, then slumped 204.11% in 2020.
- Over 5 years, Net Cash Flow stood at -$9007.4 in 2018, then jumped by 95722.48% to $8.6 million in 2019, then plunged by 204.11% to -$9.0 million in 2020, then jumped by 96.57% to -$307346.4 in 2021, then surged by 63.75% to -$111428.2 in 2022.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$111428.2, -$117489.0, and -$307346.4 for Q4 2022, Q3 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -111,428.19 |
| Dec 31, 2022 | -111,428.19 |
| Sep 14, 2022 | -117,488.97 |
| Sep 14, 2022 | -117,488.97 |
| Dec 31, 2021 | -307,346.42 |
| Dec 31, 2021 | -307,346.42 |
| Sep 17, 2021 | -4.64 Mn |
| Sep 17, 2021 | -4.64 Mn |
| Dec 31, 2020 | -8.97 Mn |
| Dec 31, 2020 | -8.97 Mn |
| Sep 10, 2020 | -8.55 Mn |
| Sep 10, 2020 | -8.55 Mn |
| Dec 31, 2019 | 8.61 Mn |
| Dec 31, 2019 | 8.61 Mn |
| Dec 31, 2018 | -9,007.37 |
| Dec 31, 2018 | -9,007.37 |
| Dec 31, 2017 | 45,140.60 |
| Dec 31, 2017 | 45,140.60 |
| Dec 31, 2016 | -16.28 Mn |
| Dec 31, 2016 | -16.28 Mn |